Immune Design (IMDZ) Trading -6% Higher

Immune Design Corp (NASDAQ:IMDZ) shares traded up 6% on Tuesday . The company traded as high as $4.10 and last traded at $3.90. 631,600 shares were traded during trading, an increase of 92% from the average session volume of 329,466 shares. The stock had previously closed at $4.15.

A number of research analysts recently weighed in on the company. Zacks Investment Research raised Immune Design from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research note on Tuesday. Royal Bank of Canada began coverage on Immune Design in a research note on Thursday, September 14th. They issued an “outperform” rating and a $20.00 price objective for the company. ValuEngine downgraded Immune Design from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Cowen reissued a “buy” rating on shares of Immune Design in a research note on Monday, December 11th. Finally, Wells Fargo & Co downgraded Immune Design from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $29.00 to $10.00 in a research note on Tuesday, October 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $13.06.

The firm has a market cap of $197.04, a P/E ratio of -1.92 and a beta of 2.36.

Immune Design (NASDAQ:IMDZ) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.11. The firm had revenue of $0.52 million during the quarter, compared to the consensus estimate of $0.62 million. Immune Design had a negative return on equity of 68.69% and a negative net margin of 619.62%. analysts predict that Immune Design Corp will post -1.89 EPS for the current fiscal year.

In other Immune Design news, Director Franklin M. Berger bought 25,000 shares of Immune Design stock in a transaction dated Wednesday, October 25th. The stock was bought at an average cost of $4.26 per share, with a total value of $106,500.00. Following the completion of the acquisition, the director now directly owns 50,000 shares in the company, valued at approximately $213,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Leo Guthart bought 10,000 shares of Immune Design stock in a transaction dated Thursday, October 19th. The stock was acquired at an average cost of $6.09 per share, with a total value of $60,900.00. The disclosure for this purchase can be found here. Over the last three months, insiders bought 5,290,000 shares of company stock valued at $21,777,900. Company insiders own 20.70% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. State of Wisconsin Investment Board bought a new position in shares of Immune Design in the second quarter valued at approximately $117,000. Alliancebernstein L.P. bought a new position in shares of Immune Design in the second quarter valued at approximately $118,000. Bank of America Corp DE grew its holdings in shares of Immune Design by 123.3% in the first quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 8,418 shares in the last quarter. Virtu KCG Holdings LLC bought a new position in shares of Immune Design in the second quarter valued at approximately $153,000. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Immune Design by 9.3% in the second quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock valued at $184,000 after acquiring an additional 1,600 shares in the last quarter. 29.34% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.chaffeybreeze.com/2018/01/03/immune-design-imdz-trading-6-higher.html.

Immune Design Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply